Adjuvant skin-sparing electrochemotherapy in a breast cancer patient with a prosthetic implant: 5-year follow-up outcomes
Affiliation
Department of Surgery, The Christie NHS Foundation Trust, Manchester, UK.Issue Date
2022
Metadata
Show full item recordAbstract
A 55-year-old woman with previous skin-sparing mastectomy and prosthetic reconstruction for multifocal ductal carcinoma developed homolateral axillary recurrence. Following nodal dissection, partial periprosthetic capsulectomy and the overlying breast skin excision, the pathology report revealed a positive cutaneous margin. Since further breast skin excision or radiotherapy would have compromised the prosthetic implant, and the patient was adamant about avoiding any endangering intervention, the multidisciplinary recommendation included skin-directed electrochemotherapy (ECT) in the frame of a multimodal treatment strategy. The procedure lasted 20 minutes under mild general sedation and included a bolus of intravenous bleomycin followed by local application of electric pulses using a needle electrode. The postprocedural course was uneventful, except for mild dermatologic toxicity. At 5 years, the patient is disease-free with the implant in situ. This report illustrates the proof-of-concept of adjuvant skin-sparing ECT to sterilize resection margins, preserve a breast implant and highlight procedural details to avert toxicity.Citation
Campana LG, Balestrieri N, Menin N. Adjuvant skin-sparing electrochemotherapy in a breast cancer patient with a prosthetic implant: 5-year follow-up outcomes. Vol. 2022, Journal of Surgical Case Reports. Oxford University Press (OUP); 2022.Journal
Journal of Surgical Case ReportsDOI
10.1093/jscr/rjac199PubMed ID
35599994Additional Links
https://dx.doi.org/10.1093/jscr/rjac199Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/jscr/rjac199